Xlr3a Inhibitors
Chemical inhibitors of Xlr3a operate through various molecular mechanisms to inhibit its function. LY294002 and Wortmannin, for example, are both inhibitors of PI3K, a kinase involved in critical signaling pathways such as AKT activation that affect a range of cellular processes. By inhibiting PI3K, these chemicals impede the pathway's function, leading to a reduction in the activities of Xlr3a that are dependent on PI3K signaling. Similarly, PD98059 and U0126 target the MEK enzymes, which are upstream regulators of ERK in the MAPK pathway. The MAPK pathway is integral for various cellular functions, and by inhibiting MEK, PD98059 and U0126 prevent the activation of ERK. This disruption halts the signaling processes in which Xlr3a is involved, thus inhibiting its function.
Additional inhibitors, such as SB203580, SP600125, and Y-27632, target other kinases involved in cell signaling. SB203580 specifically inhibits p38 MAP kinase, which plays a role in stress response and apoptosis, thereby affecting Xlr3a functions tied to these responses. SP600125 inhibits JNK, which prevents the phosphorylation of transcription factors that are crucial for cell cycle and apoptosis, leading to an inhibition of Xlr3a's activity in these pathways. Y-27632, on the other hand, inhibits ROCK, which is significant for actin cytoskeleton organization and cell motility, processes that can be regulated by Xlr3a. Furthermore, Alsterpaullone, Roscovitine, Purvalanol A, Olomoucine, and Indirubin-3'-monoxime are all inhibitors of cyclin-dependent kinases (CDKs). CDKs are key players in cell cycle regulation, and their inhibition by these chemicals results in a disruption of cell cycle checkpoints and transcriptional regulation, which can lead to an inhibition of any cell cycle-dependent activity of Xlr3a. These inhibitors collectively cover a broad spectrum of the biochemical pathways that govern the functional activity of Xlr3a.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. Since PI3K signaling is crucial for a multitude of cellular processes, including those related to cytoskeletal organization, gene expression, and cell survival, inhibition by LY294002 can lead to a reduction in the cellular activities in which Xlr3a is involved, thereby inhibiting Xlr3a functionally. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor. By inhibiting MEK, PD98059 prevents the activation of ERK, a downstream effector in the MAPK pathway. As Xlr3a operates within cellular processes governed by the MAPK pathway, inhibition of this pathway can lead to functional inhibition of Xlr3a. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. The p38 MAPK pathway is implicated in stress response and apoptosis. By inhibiting p38 MAP kinase, SB203580 can disrupt processes in which Xlr3a is functionally involved, leading to its inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, thereby preventing the phosphorylation and activation of c-Jun and other transcription factors. As JNK signaling can regulate proteins involved in cell cycle and apoptosis, inhibiting JNK can functionally inhibit the activity of Xlr3a by curtailing the cellular responses it mediates. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream regulators of ERK in the MAPK pathway. By blocking MEK1/2, U0126 impairs the activation of ERK and thus can inhibit the functional activity of Xlr3a by stalling the signaling processes it influences. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. Inhibition of PI3K by Wortmannin can result in the functional inhibition of Xlr3a by obstructing the PI3K/AKT pathway which may govern processes essential for Xlr3a's activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor. The ROCK pathway is significant for actin cytoskeleton organization and cell motility. By inhibiting ROCK, Y-27632 can lead to functional inhibition of Xlr3a by altering the cytoskeletal dynamics that Xlr3a may regulate. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor. CDKs are key regulators of the cell cycle, and by inhibiting these kinases, Alsterpaullone can functionally inhibit Xlr3a if it is involved in cell cycle regulation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine is a selective inhibitor of CDKs. It can inhibit Xlr3a by hindering cell cycle progression and transcriptional regulation if Xlr3a's function is coupled with CDK-regulated processes. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
Purvalanol A is another CDK inhibitor. By targeting CDKs, Purvalanol A can functionally inhibit Xlr3a activity by disrupting cell cycle checkpoints and processes that are essential for Xlr3a's action. | ||||||